27. Fu EL, Mastrorilli J, Bykov K, et al.. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disea...
27. Fu EL, Mastrorilli J, Bykov K, et al.. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes. Kidney Int 2024;105:618-28. 10.1016/j.kint.2023.11...
二肽基肽酶-4 (Dipeptidyl peptidase-4, DPP-4)抑制剂可阻断GLP-1和GIP的体内失活,增加内源性活性激素的水平。而GLP-1受体激动剂(GLP-1 RA)是exendin-4或人GLP-1的肽衍生物,旨在激活激素受体,抵抗DPP-4的活性,GLP-1 RA 使GLP-1水平增加幅度更明显,因此较DPPi降糖效果更好。在真实世界临床实践中,GLP-1...
Conclusion:The GLP-1 receptor agonists for the treatment of type 2 diabetes,on which clinical curative effect is better than that of DPP-4 inhibitors,and no severe adverse reaction,It should be worth promoting. 【keyword】Glucagon like peptide-1 receptor agonist;Two dipeptidyl peptidase -4;Type ...
[2] Longato, E. , Camillo, B. D. , Sparacino, G. , Tramontan, L. , & Fadini, G. P. . (2020). Better cardiovascular outcomes of type 2 diabetic patients treated with glp-1 receptor agonists versus dpp-4 inhibitors in ...
[1] Gilbert, M. P. , & Pratley, R. E. . (2020). Glp-1 analogs and dpp-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Frontiers in Endocrinology, 11. [2] Longato, E. , Camillo, B. D. , Sparacino, G. , Tramontan, L. , & Fadini, G....
This disclosure relates to GLP-1 pathway agonists and DPP -2 inhibitors and uses related thereto. In certain embodiments, the disclosure relates to methods of improving organ transplants and preventing ischemic injury. In certain embodiments the disclosure relates to organ, cell, or tissue ...
Dr. Pratley discussed the role of DPP-IV inhibitors in the treatment of diabetes. Both GLP-1 and GIP have the amino acid alanine in the second N-terminal position, leading to inactivation by DPP-IV. It is interesting that more than half of secreted GLP-1 is degraded by local DPP-IV ...
Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose co-transporter-2 (SGLT-2) inhibitors reduce cardiorenal outcomes. We performed a network meta-analysis to compare the effect on cardiorenal outcomes among GLP-1 RAs, SGLT-2 inhibitors and dipeptidyl peptidase-4 (DPP-4) inhib...
原文来自:Zareini B, Sørensen KK, Pedersen-Bjergaard U, Loldrup Fosbøl E, Køber L, Torp-Pedersen C. Glucagon-like-peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes in...